Medrio, a global leader in clinical trial technology, announced significant enhancements to its randomization and trial supply management (RTSM) solution on March 26, 2025. The upgraded platform delivers faster implementation timeframes, greater flexibility, and enhanced self-service capabilities designed to streamline clinical trial operations.
The enhancements come at a critical time for the industry, as the latest IRT Benchmarking & Market Dynamics report reveals that 77% of clinical trials now require moderate to high-complexity RTSM builds, highlighting the growing need for more adaptable and configurable systems.
"Our customers need RTSM to be as agile as the trials they run," said Nicole Latimer, Chief Executive Officer at Medrio. "By expanding our configurability capabilities, we're allowing teams to build, test, and deploy Medrio RTSM in a fraction of the time of traditional systems without relying on extensive vendor support."
No-Code Configuration Accelerates Trial Timelines
The enhanced Medrio RTSM solution was designed in collaboration with customers to eliminate the barriers and complexity associated with traditional vendor-dependent setups. Its no-code configurability enables sponsors and Contract Research Organizations (CROs) to build and deploy RTSM systems in weeks rather than months, significantly accelerating study startup timelines.
Kenneth Homer, Director of Biostatistics and Programming at Homer Biometrics, LLC, who has worked with the platform, shared his experience: "The Medrio RTSM build team has been great to work with, showing knowledge, professionalism, flexibility, and the ability to meet study timelines. I am looking forward to Medrio releasing their front end, allowing us to configure the RTSM system on demand. This will be invaluable in helping us meet the needs of our clients."
Seamless Integration Enhances Data Management
A key advantage of the enhanced solution is its seamless integration with the Medrio CDMS/EDC (Clinical Data Management System/Electronic Data Capture) platform. This integration delivers a unified trial management experience that eliminates data silos, reduces reconciliation efforts, and ensures real-time data synchronization across systems.
The platform also features automated supply management, point-and-click configurability, and mid-study adaptability, allowing research teams to quickly adjust to protocol changes while maintaining comprehensive oversight and control throughout the trial lifecycle.
Advanced Features Support Complex Trial Designs
The latest evolution of Medrio's RTSM solution includes several advanced features designed to support increasingly complex clinical trial designs:
- Automated supply management with predictive algorithms to optimize inventory
- Point-and-click configurability for rapid setup and modifications
- Mid-study adaptability to accommodate protocol amendments
- Real-time data synchronization with EDC systems
- AI-enabled reporting for enhanced operational insights
These innovations underscore Medrio's commitment to advancing clinical trial efficiency and reducing study timelines. By removing barriers to speed and usability, the platform enables research teams to focus on delivering high-quality data while accelerating overall trial execution.
Availability and Implementation Support
Medrio RTSM is available now, with expanded self-service functionality scheduled to roll out throughout 2025. Customers can leverage Medrio's tiered enablement packages and expert support to optimize their RTSM workflows according to specific trial requirements.
The company's approach combines technological innovation with practical implementation support, addressing the end-to-end needs of modern clinical trials. This comprehensive strategy aligns with Medrio's stated mission to improve 100 million lives through faster, more efficient, and secure clinical trials.
With almost two decades of industry experience, Medrio continues to deliver solutions to pharmaceutical, biotech, medical device, and diagnostics companies seeking to optimize their clinical operations and regulatory readiness.
